Acyclovir: Difference between revisions
From IDWiki
(Created page with "* Acyclic guanosine analog that competes with deoxyguanosine triphosphate to inhibit viral DNA polymerase * Resistance mediated by mutation in or decrease of thymidine kinase...") |
No edit summary |
||
| Line 1: | Line 1: | ||
| − | * |
+ | *Acyclic guanosine analog that competes with deoxyguanosine triphosphate to inhibit viral DNA polymerase |
| − | * |
+ | *Resistance mediated by mutation in or decrease of thymidine kinase |
| − | * |
+ | *Adverse drug reactions include: |
| − | ** |
+ | **[[Adverse drug reaction::Acute kidney injury]] from crystal deposition, so maintain hydration |
| − | ** Phlebitis |
+ | **[[Adverse drug reaction::Phlebitis]] |
| − | ** Neurotoxicity, with lethargy, confusion, tremor, myoclonus, agitation, hallucinations, and extrapyramidal symptoms |
+ | **[[Adverse drug reaction::Neurotoxicity]], with lethargy, confusion, tremor, myoclonus, agitation, hallucinations, and extrapyramidal symptoms |
[[Category:Antivirals]] |
[[Category:Antivirals]] |
||
Revision as of 10:02, 12 August 2020
- Acyclic guanosine analog that competes with deoxyguanosine triphosphate to inhibit viral DNA polymerase
- Resistance mediated by mutation in or decrease of thymidine kinase
- Adverse drug reactions include:
- Acute kidney injury from crystal deposition, so maintain hydration
- Phlebitis
- Neurotoxicity, with lethargy, confusion, tremor, myoclonus, agitation, hallucinations, and extrapyramidal symptoms
References
- ^ Tony H. Huynh, Mark W. Johnson, Grant M. Comer, Douglas N. Fish. Vitreous Penetration of Orally Administered Valacyclovir. American Journal of Ophthalmology. 2008;145(4):682-686. doi:10.1016/j.ajo.2007.11.016.
